Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

While it’s put more em­pha­sis on be­com­ing an “im­munol­o­gy pow­er­house” in re­cent quar­ters, Sanofi still shows signs of in­ter­est in on­col­o­gy.

On Thurs­day it an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER